Schoppmann SF, Jesch B, Zacherl J, Wrba F,
Hejna M, Maresch J, Langer FB, Riegler MF,
Pluschnig U, Birner P (2011) HER-2 status in
primary esophageal cancer, lymph nodes and
distant metastases. Br J Surg 98:1408–1413
Wong DD, de Boer WB, Platten MA, Jo VY,
Cibas ES, Kumarasinghe MP (2015) HER2
testing in malignant effusions of metastatic gas-
tric carcinoma: is it feasible? Diagn Cytopathol
43:80–85
Goldstein NS, Hewitt SM, Taylor CR, Yaziji
H, Hicks DG, Members of Ad-Hoc Committee
on Immunohistochemistry Standardization
(2007) Recommendations for improved stan-
dardization of immunohistochemistry. Appl
Immunohistochem Mol Morphol 15:124–133
Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ,
Hammond EH, Hewlett B, Floyd AD, Barry
TS, Martin AW, Badve S, Baehner F, Cartun
RW, Eisen RN, Swanson PE, Hewitt SM,
Vyberg M, Hicks DG, Members of the
Standardization Ad-Hoc Consensus
Committee (2008) Consensus recommenda-
tions on estrogen receptor testing in breast
cancer by immunohistochemistry. Appl
Immunohistochem Mol Morphol 16:513–520
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL,
Francis G, Goldstein NS, Hayes M, Hicks DG,
Lester S, Love R, Mangu PB, McShane L,
Miller K, Osborne CK, Paik S, Perlmutter J,
Rhodes A, Sasano H, Schwartz JN, Sweep FC,
Taube S, Torlakovic EE, Valenstein P, Viale G,
Visscher D, Wheeler T, Williams RB, Wittliff
JL, Wolff AC (2010) American Society of
Clinical Oncology/College of American
Pathologists guideline recommendations for
immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. Arch
Pathol Lab Med 134:907–922
Wolff AC, Hammond ME, Hicks DG, Dowsett
M, McShane LM, Allison KH, Allred DC,
Bartlett JM, Bilous M, Fitzgibbons P, Hanna W,
Jenkins RB, Mangu PB, Paik S, Perez EA, Press
MF, Spears PA, Vance GH, Viale G, Hayes DF,
American Society of Clinical Oncology; College
of American Pathologists (2013)
Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College
of American Pathologists clinical practice guide-
line update. J Clin Oncol 31:3997–4013
Rüschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, Penault-Llorca F, van de Vijver
M, Viale G (2012) HER2 testing in gastric
cancer: a practical approach. Mod Pathol
25:637–650
35. Grogan TM, Grogan T, McElhinny A, Loftin I
et al (2012) Interpretation Guide Ventana
INFORM HER2 Dual ISH DNA Probe Cocktail
Assay. Ventana Medical Systems Inc., Tucson,
AZ, USA. http://productlibrary.ventana.com/
ventana_portal/OpenOverlayServlet?launchInde
x=1&objectId=780-4422101070200
36. Heras A, King G, Oroudjev E, Vargas J, Flores
EL, Romo MAG, Osorno AZ, Hidalgo CO,
Key M (2011) Hydrophilic plus slides: a
surface- modified microscope slide for improved
tissue adhesion. Bio SB, Santa Barbara, CA,
USA. http://www.biosb.com/wp-content/
uploads/Final-Hydrophilic-Plus-Slides-for-
Molecular-Pathology.pdf
37. Rakha EA, Pinder SE, Bartlett JMS et al (2015)
Updated UK Recommendations for HER2
assessment in breast cancer. J Clin Pathol
68:93–99
38. Xie R, Chung JY, Ylaya K, Williams RL,
Guerrero N, Nakatsuka N, Badie C, Hewitt SM
(2011) Factors influencing the degradation of
archival formalin- fixed paraffin-embedded tissue
sections. J Histochem Cytochem 59:356–365
39. Li X, Chew SH, Chay WY, Lim-Tan SK, Goh
LK (2013) Optimizing Ventana chromogenic
dual in-situ hybridization for mucinous epithe-
lial ovarian cancer. BMC Res Notes 6:562
40. HER2/neu (4B5) Rabbit Monoclonal Primary
Antibody, VENTANA [package insert] (2011)
Ventana Medical Systems Inc., Tucson, AZ,
USA. http://productlibrary.ventana.com/
ventana_portal/OpenOverlayServlet?launchIn
dex=1&objectId=790-44931007199EN
41. Sapino A, Goia M, Recupero D, Marchiò C
(2013) Current challenges for HER2 testing in
diagnostic pathology: state of the art and con-
troversial issues. Front Oncol 3:129
42. INFORM HER2 Dual ISH DNA PROBE
Cocktail Assay, VENTANA [package insert]
(2016). Ventana Medical Systems Inc., Tucson,
AZ, USA. http://productlibrary.ventana.
com/ventana_portal/OpenOverlayServlet?lau
nchIndex=1&objectId=800-44221008041EN
43. Brügmann A, Lelkaitis G, Nielsen S, Jensen
KG, Jensen V (2011) Testing HER2 in breast
cancer: a comparative study on BRISH, FISH,
and IHC. Appl Immunohistochem Mol
Morphol 19:203–211
44. HER2 IQFISH pharmDx, for Dako Omnis,
DAKO [package insert]. Dako Denmark A/S.,
Glostrup, Denmark. http://www.chem.agi-
lent.com/cs/library/packageinsert/pub-
lic/127859001.PDF
45. Hofmann M, Stoss O, Shi D, Büttner R, van de
Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel
